Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline

 Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline

Shots:

  • WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized from the panel
  • Exelixis get an exclusive license to the panel of mAb against an undisclosed oncology target for biologics applications
  • Exelixis leverages WuXi Bio’s integrated technology platforms to develop ADC, bispecific, and certain other novel tumor-targeting biologics applications

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Exelixis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post